Incidence
Retinoblastoma (Rb) is the most common intraocular malignancy of childhood, but a relatively rare disease, occurring in approximately 1: 16,000-18,000 live births. 1 Its incidence is uniform across populations, with no gender or ethnic predilection and no environmental or socio-economic factors. Worldwide, approximately 8,000 children develop Rb each year. Of these, over 80% are from low-to middle-income countries from Asia and Africa. Rb develops in early childhood, with the vast majority of cases presenting before the age of 5 years.
Aetiology
Rb can be inherited or develop de novo (sporadic) in a child with no family history of Rb. The cancer can involve one or both eyes and may present in an asymmetrical manner, with different grade eyes at presentation or even a unilateral presentation, with disease developing in the other eye later. The disorder originates in a photoreceptor cell of the retina early in childhood. In most instances, there is a mutation in the RB1 gene. RB1 loss initially produces a retinoma (Figure 1 ), the benign precursor of Rb, and causes genomic instability that subsequently leads to the cancerous tumour known as retinoblastoma. Interestingly, retinomas should be looked for and can be found in the parents of affected children, confirming that the disease is inherited in that family.
Characteristics of hereditary and sporadic disease
Patients diagnosed with Rb are categorised by whether the mutation is germline or non-germline (i.e. somatic). In germline disease, a single RB1 allele is mutated in every cell of a child's body. An additional 'hit' in the second allele in the developing retina will result in clinical Rb. These children usually present with bilateral and multifocal disease (Figure 2 ) at a young age, median of 15 months, but can present with unliteral disease, albeit less frequently. A patient that presents with bilateral disease is 100% germline. However, it is estimated that 10-20 % of unilateral cases are also germline, emphasising the importance of genetic testing in addition to clinical examination.
Somatic (non-germline) cases usually present at a later age (median: 24 months) with unilateral and unifocal disease. In order for the disease to develop in somatic cases, two consecutive 'hits' need to occur in a retinal cell, resulting in mutation of both RB1 alleles and development of clinical Rb.
Mosaicism
All heritable cases are germline, but not all germline cases have a familial history. This is because a mutation can occur at or after conception in an individual with no family history of Rb. Depending on the stage of development at which the mutation occurs, some of the foetus' cells will have a mutated RB1 allele, and others will not, resulting in a mosaicism. Children with mosaicism are at increased risk of developing Rb. The disease in this scenario has no family history. The siblings of the affected child are not at risk, but offspring may be at risk and should therefore be screened soon after birth. 
Developing Rb genetics and counselling
It was long believed that mutated RB1 genes are a prerequisite to develop Rb. Recently, however, researchers have found that Rb may arise even in the presence of non-mutated RB1 genes when the MYCN oncogene is amplifi ed.
2 These cases are relatively rare, occurring in <3% of unilateral Rb cases, and present earlier, at a median age of 4.5 months.
The fi eld of Rb molecular genetics has evolved signifi cantly since the RB1 gene was cloned in the mid-1980's.
2 Today, genetic laboratories are able to detect specifi c mutations and correlate them to the probability of developing Rb in an individual and her or his relatives. It has also set the basis for the development of screening programmes, which are discussed by Rosser et al in the current issue.
Knowledge of the genetic status has direct impact on the recommended screening frequency and also on the recommended screening protocol for siblings and off spring. Individuals harboring a germline mutation are also at risk of developing secondary non-Rb malignancies later in life, a risk that is further intensifi ed if treated with external-beam radiotherapy, a treatment modality that used to be commonly used for Rb.
3
Genetic testing, however, is not available in all centres across the world, being particularly sparse in low-resource countries. Much eff ort is put into improving Rb management and public health related to Rb in these countries. Genetic testing and screening will depend on genetic services being developed in these settings. Until then, clinicians should use epidemiological and clinical signs, including the age of presentation, laterality, tumour focality, presence of retinoma in a parent and family history of Rb, to counsel patients and their families.
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How we manage patients with retinoblastoma
Vikas Khetan Senior Consultant: Sankara Nethralaya, Chennai, India.
When a child with retinoblastoma reports to our centre, a message is immediately passed on to a physician who treats retinoblastoma.
The child is then expedited to reach the physician, where a proper history is taken. After initial evaluation, drops are applied for pupillary dilatation. After the dilatation, the fundi are examined and a quick assessment of tumor volume and initial staging and grouping of the tumour in the eyes is made.
The child then undergoes ultrasound of both eyes, irrespective of it being unilateral presentation. An MRI of the orbits and brain is then advised. The MRI usually happens the same day and reporting takes place within a few hours. Once this information is available, the child is scheduled for an examination under general anaesthesia. Following this, the treatment plan is discussed with the parents.
In case of an orbital presentation, or an MRI showing optic nerve involvement, additional testing in the form of cerebrospinal fl uid (CSF) analysis and a bone marrow aspirate is conducted and evaluated. Staging of the tumour is then performed as per the tests.
If enucleation is planned, we always ask for an opinion from another retinoblastoma expert.
The option of performing genetic testing is also discussed with the parents; however, this is not routinely done as a standard of care as the testing is often expensive and not many parents can aff ord it. Our aim therefore shifts to the management of the child.
We have an ocular oncologist in the team who visits our hospital to examine these children in case they require chemotherapy. We are also equipped to perform brachytherapy when needed. 
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